First-half sales of 30.36 billion Swiss francs topped analyst expectations as pharmaceuticals helped drive growth and the Swiss drugmaker reiterated its full-year guidance.
Roche reaffirmed its 2026 guidance after first-half sales rose 6% at constant exchange rates to 30.36 billion Swiss francs, beating analyst expectations of 30.27 billion Swiss francs. The pharmaceuticals division helped drive the increase, supporting the Swiss drugmaker’s outlook despite pressure from a stronger Swiss franc on reported figures. Earlier disclosed results showed group sales were down 2% in Swiss francs, while core operating profit rose 10% at CER to CHF 11.9 billion and IFRS operating profit fell 6% in Swiss francs to CHF 9.7 billion. Core diluted earnings per share increased 9% at CER, while IFRS diluted earnings per share declined 8% in Swiss francs. The Pharmaceuticals Division posted sales of CHF 23.6 billion, up 6% at CER, led by Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo. Diagnostics sales reached CHF 6.7 billion, up 3% at CER. Roche also highlighted regulatory and pipeline progress, including five U.S. Priority Reviews, phase III data updates and diagnostics product launches, as it maintained its expectation for mid single-digit sales growth at CER in 2026 and high single-digit core earnings per share growth at CER.